MedTrace Logo

A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis

NCT06900192 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-03-28

No results posted yet for this study

Summary

A study of alloHCT with Orca-Q for the treatment of primary progressive multiple sclerosis (MS).

Conditions

Interventions

BIOLOGICAL

Orca-Q

Allogeneic (donor) stem cell graft

DRUG

myeloablative regimen

Myeloablative regimen of busulfan, fludarabine, and thiotepa.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2029-08-31
Completion
2029-08-31
FDA Drug
Yes

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06900192 on ClinicalTrials.gov